Research ExplorerPublicationsMultipotent Mesenchymal Stromal Cells: Possible Culprits in ...

Multipotent Mesenchymal Stromal Cells: Possible Culprits in Solid Tumors?

Standard

Multipotent Mesenchymal Stromal Cells: Possible Culprits in Solid Tumors? / Johann, Pascal David; Müller, Ingo.

In: Stem Cells Int, Vol. 2015, 2015, p. 914632.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Johann, PD & Müller, I 2015, 'Multipotent Mesenchymal Stromal Cells: Possible Culprits in Solid Tumors?', Stem Cells Int, vol. 2015, pp. 914632. https://doi.org/10.1155/2015/914632

APA

Johann, P. D., & Müller, I. (2015). Multipotent Mesenchymal Stromal Cells: Possible Culprits in Solid Tumors? Stem Cells Int, 2015, 914632. https://doi.org/10.1155/2015/914632

Vancouver

Johann PD, Müller I. Multipotent Mesenchymal Stromal Cells: Possible Culprits in Solid Tumors? Stem Cells Int. 2015;2015:914632. https://doi.org/10.1155/2015/914632

Bibtex

@article{a1f8093b3f964e4aac1415683353fdd8,
title = "Multipotent Mesenchymal Stromal Cells: Possible Culprits in Solid Tumors?",
abstract = "The clinical use of bone marrow derived multipotent mesenchymal stromal cells (BM-MSCs) in different settings ranging from tissue engineering to immunotherapies has prompted investigations on the properties of these cells in a variety of other tissues. Particularly the role of MSCs in solid tumors has been the subject of many experimental approaches. While a clear phenotypical distinction of tumor associated fibroblasts (TAFs) and MSCs within the tumor microenvironment is still missing, the homing of bone marrow MSCs in tumor sites has been extensively studied. Both, tumor-promoting and tumor-inhibiting effects of BM-MSCs have been described in this context. This ambiguity requires a reappraisal of the different studies and experimental methods employed. Here, we review the current literature on tumor-promoting and tumor-inhibiting effects of BM-MSCs with a particular emphasis on their interplay with components of the immune system and also highlight a potential role of MSCs as cell of origin for certain mesenchymal tumors.",
author = "Johann, {Pascal David} and Ingo M{\"u}ller",
year = "2015",
doi = "10.1155/2015/914632",
language = "English",
volume = "2015",
pages = "914632",
journal = "Stem Cells Int",
issn = "1687-966X",
publisher = "Hindawi Publishing Corporation",

}

RIS

TY - JOUR

T1 - Multipotent Mesenchymal Stromal Cells: Possible Culprits in Solid Tumors?

AU - Johann, Pascal David

AU - Müller, Ingo

PY - 2015

Y1 - 2015

N2 - The clinical use of bone marrow derived multipotent mesenchymal stromal cells (BM-MSCs) in different settings ranging from tissue engineering to immunotherapies has prompted investigations on the properties of these cells in a variety of other tissues. Particularly the role of MSCs in solid tumors has been the subject of many experimental approaches. While a clear phenotypical distinction of tumor associated fibroblasts (TAFs) and MSCs within the tumor microenvironment is still missing, the homing of bone marrow MSCs in tumor sites has been extensively studied. Both, tumor-promoting and tumor-inhibiting effects of BM-MSCs have been described in this context. This ambiguity requires a reappraisal of the different studies and experimental methods employed. Here, we review the current literature on tumor-promoting and tumor-inhibiting effects of BM-MSCs with a particular emphasis on their interplay with components of the immune system and also highlight a potential role of MSCs as cell of origin for certain mesenchymal tumors.

AB - The clinical use of bone marrow derived multipotent mesenchymal stromal cells (BM-MSCs) in different settings ranging from tissue engineering to immunotherapies has prompted investigations on the properties of these cells in a variety of other tissues. Particularly the role of MSCs in solid tumors has been the subject of many experimental approaches. While a clear phenotypical distinction of tumor associated fibroblasts (TAFs) and MSCs within the tumor microenvironment is still missing, the homing of bone marrow MSCs in tumor sites has been extensively studied. Both, tumor-promoting and tumor-inhibiting effects of BM-MSCs have been described in this context. This ambiguity requires a reappraisal of the different studies and experimental methods employed. Here, we review the current literature on tumor-promoting and tumor-inhibiting effects of BM-MSCs with a particular emphasis on their interplay with components of the immune system and also highlight a potential role of MSCs as cell of origin for certain mesenchymal tumors.

U2 - 10.1155/2015/914632

DO - 10.1155/2015/914632

M3 - SCORING: Journal article

C2 - 26273308

VL - 2015

SP - 914632

JO - Stem Cells Int

JF - Stem Cells Int

SN - 1687-966X

ER -